|Description||Diabetic neuropathies (DNs) are nerve damaging disorders caused by diabetes. Diabetic neuropathy broadly comprise generalized symmetric polyneuropathies (acute sensory, chronic sensorimotor, autonomic) and asymmetric (focal and multifocal) neuropathies (cranial, truncal, focal-limb, proximal-motor, coexisting chronic inflammatory demyelinating), which affect all organs and system. Of all types, diabetic sensorimotor polyneuropathy (DSPN), also called distal symmetric neuropathy, is the most typical form. Typical Symptoms vary from person to person, but may include numbness, tingling, pain, or weakness that typically starts in the feet and progresses up the legs. This pattern of neuropathy shows a progressive distal axonopathy. It has been reported that vascular endothelial growth factor A is associated with DNs development and progression.|
|Category||Metabolic disease; Endocrine disease; Nervous system disease|
|Gene||Vascular endothelial growth factor A (polymorphism) [hsa:7422] [KO:K05448]|
|Drug||Mexiletine [DG:DG00197] (Sodium channel blocking type (class I) antiarrhythmics)
Duloxetine [DG:DG00962] (Antidepressants)
Pregabalin [DR:D02716] (Calcium channel alpha-2 delat blocker)
Tapentadol [DG:DG00826] (Opioid analgesics)
|Comment||Pregabalin [DR:D02716] (US and EU approved)|
|Other DBs||ICD-10: E14.4
Vinik A, Ullal J, Parson HK, Casellini CM
Diabetic neuropathies: clinical manifestations and current treatment options.
Nat Clin Pract Endocrinol Metab 2:269-81 (2006)
Gupta A, Gupta Y
Diabetic neuropathy: Part 1.
J Pak Med Assoc 64:714-8 (2014)
Bansal V, Kalita J, Misra UK
Postgrad Med J 82:95-100 (2006)
Witzel II, Jelinek HF, Khalaf K, Lee S, Khandoker AH, Alsafar H
Identifying Common Genetic Risk Factors of Diabetic Neuropathies.
Front Endocrinol (Lausanne) 6:88 (2015)
Adeghate E, Feher E, Kalasz H
Evaluating the Phase II drugs currently under investigation for diabetic neuropathy.
Expert Opin Investig Drugs 24:1-15 (2015)
Vinik A, Casellini C, Nevoret ML